Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Here's Why Galapagos NV Stock Rose 13.4% in June

By Maxx Chatsko - Jul 9, 2019 at 12:52PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The good news keeps rolling in for this Belgian pharma.

What happened

Shares of Galapagos NV ( GLPG 0.00% ) jumped over 13% last month and have posted a year-to-date gain of 49% through the first week of July, according to data provided by S&P Global Market Intelligence. While much of the pharma specialist's recent stock movements have been driven by the JAK1 inhibitor filgotinib, the only pipeline update in June was for GLPG1972 in knee osteoarthritis -- but investors have reason to be cautiously excited.

Galapagos and Servier announced that a phase 2 trial for GLPG1972 completed enrollment in mid-June. The global trial spans 850 patients in 12 countries. It will be another year or so before initial data is available, but the drug candidate represents a significant long-term opportunity for the business and its shareholders. 

A rising yellow chart being drawn by a man in a suit.

Image source: Getty Images.

So what

The stock's current run began in March, when Galapagos and Gilead Sciences announced that filgotinib aced two pivotal trials in rheumatoid arthritis. Fool.com contributor George Budwell noted that some analysts expect peak annual sales of $1.1 billion in that indication alone, although gaining approval in additional autoimmune diseases could push peak annual sales to $6.6 billion or more. 

In early July, Galapagos announced it will submit a New Drug Application for filgotinib to the U.S. Food and Drug Administration (FDA) this calendar year. That promises to keep it as the main catalyst for the stock, but it won't be the only one. 

GLPG1972 is billed as a disease-modifying osteoarthritis drug candidate because it mops up a cartilage-degrading enzyme that leads to the disease. In a phase 1 trial, the drug reduced a biomarker of cartilage breakdown by 50% after just two weeks. Delivering similar results -- and proving they're actually relevant to patients -- in the more robust phase 2 trial, which spans 52 weeks, could signal that the drug candidate has blockbuster potential. 

Now what

Given the massive market opportunity and unmet medical need, analysts at H.C. Wainwright think GLPG1972 could achieve peak annual sales of $5 billion by 2030. However, it would have to ace mid- and late-stage clinical trials, and the same analysts currently think it has a 10% probability of success. Nonetheless, the optimistic estimate goes to show that Galapagos has plenty of potential in its pipeline beyond filgotinib. 

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Galapagos Stock Quote
Galapagos
GLPG
$48.29 (0.00%) $0.00

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
634%
 
S&P 500 Returns
141%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/02/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.